Literature DB >> 15683552

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.

Jun-Sheng Wang1, Ying Ruan, Robin M Taylor, Jennifer L Donovan, John S Markowitz, C Lindsay DeVane.   

Abstract

P-glycoprotein (P-gp) in the brain capillary endothelial cell limits the entry of many drugs into the brain. Our previous in-vitro study using ATPase as a marker of P-gp activity suggested that risperidone might be effectively transported by P-gp. In the present study, we compared the concentrations of risperidone and its major pharmacologically active metabolite 9-hydroxyrisperidone (9-OH-risperidone), in plasma, brain and various other tissues between abcb1ab-/- knockout mice which are functionally devoid of P-gp in their blood-brain barrier vs. FVB wild-type mice. One hour after intraperitoneal injection of 4 microg/g risperidone, the brain concentrations and ratios of brain:plasma concentrations of risperidone (13.1-fold and 12-fold respectively, p<0.05) and 9-OH-risperidone (29.4-fold and 29-fold respectively, p<0.01) were significantly higher in the abcb1ab-/- mice than those in the FVB mice. These results indicate that P-gp in the blood-brain barrier significantly influences the brain concentrations of risperidone and 9-OH-risperidone by limiting their CNS access.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15683552     DOI: 10.1017/S1461145704004390

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  30 in total

1.  Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.

Authors:  Hee-Doo Yoo; Hea-Young Cho; Sang-No Lee; Hwa Yoon; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-24       Impact factor: 2.745

Review 2.  The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

Authors:  Jose de Leon; Margaret T Susce; Elaina Murray-Carmichael
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

3.  Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; C Lindsay DeVane
Journal:  Psychopharmacology (Berl)       Date:  2006-06-30       Impact factor: 4.530

4.  Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10.

Authors:  Hee-Doo Yoo; Sang-No Lee; Hyun-Ah Kang; Hea-Young Cho; Il-Kwon Lee; Yong-Bok Lee
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

5.  Inhibition of human MDR1 and BCRP transporter ATPase activity by organochlorine and pyrethroid insecticides.

Authors:  Kristin M Bircsak; Jason R Richardson; Lauren M Aleksunes
Journal:  J Biochem Mol Toxicol       Date:  2012-11-20       Impact factor: 3.642

6.  Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.

Authors:  Magdalena Kozielska; Martin Johnson; Venkatesh Pilla Reddy; An Vermeulen; Cheryl Li; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2012-03-22       Impact factor: 4.200

7.  The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.

Authors:  Natalia I Brzozowska; Erik J de Tonnerre; Kong M Li; Xiao Suo Wang; Aurelie A Boucher; Paul D Callaghan; Michael Kuligowski; Alex Wong; Jonathon C Arnold
Journal:  Neuropsychopharmacology       Date:  2017-03-08       Impact factor: 7.853

Review 8.  Psychotropic drug-drug interactions involving P-glycoprotein.

Authors:  Yumiko Akamine; Norio Yasui-Furukori; Ichiro Ieiri; Tsukasa Uno
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 9.  New atypical antipsychotics for schizophrenia: iloperidone.

Authors:  Silvio Caccia; Luca Pasina; Alessandro Nobili
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

10.  Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; Bryan Bradford Gibson; John Seth Markowitz; Jennifer Lyn Donovan; Carl Lindsay DeVane
Journal:  Biol Pharm Bull       Date:  2008-02       Impact factor: 2.233

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.